Provita Sp. z o.o.

The Dermatology Department at Provita Sp. z o.o. is focused on immune‑mediated conditions such as Alopecia Areata, Allergic Rhinitis/Rhinoconjunctivitis triggered by house dust mite, and Hidradenitis Suppurativa. Current studies aim to evaluate new therapies that can reduce disease activity and improve patient quality of life.

• Assessing oral JAK inhibitor upadacitinib for severe alopecia areata
• Evaluating subcutaneous immunotherapy for dust‑mite induced allergic rhinitis
• Testing biologic agent izokibep in hidradenitis suppurativa

Provita Sp. z o.o., located in Katowice, Poland, is conducting five clinical trials with a team of seven investigators, all within the immune‑system disease therapeutic area.

In the field of Skin and Connective Tissue Diseases, the department investigates disorders that affect the skin’s appearance and function, including Plaque Psoriasis, Hidradenitis Suppurativa, and Alopecia Areata. The primary goal of these trials is to test innovative treatments that target inflammation and promote skin healing.

• Investigating DC‑806 for moderate to severe plaque psoriasis
• Studying izokibep in patients with hidradenitis suppurativa
• Exploring upadacitinib’s impact on skin manifestations of alopecia areata

The Dermatology Department at Provita Sp. z o.o. currently manages five clinical studies, employing seven investigators to advance therapeutic options for skin and connective tissue diseases.